Compare AVX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | AYTU |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 27.4M |
| IPO Year | 2020 | 2015 |
| Metric | AVX | AYTU |
|---|---|---|
| Price | $4.53 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | ★ 232.4K | 19.8K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,340,811.00 | ★ $27,632,080.00 |
| Revenue This Year | $18,042.77 | $17.96 |
| Revenue Next Year | $12.21 | $27.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | 277.47 |
| 52 Week Low | $0.35 | $1.80 |
| 52 Week High | $7.38 | $3.07 |
| Indicator | AVX | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 46.02 |
| Support Level | $3.02 | $1.94 |
| Resistance Level | $6.25 | $2.34 |
| Average True Range (ATR) | 0.65 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 39.83 | 33.33 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.